AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
UniQure Stock Soars 38.55% on FDA Breakthrough Therapy Designation
Generated by AI AgentAinvest Movers Radar
Friday, Apr 18, 2025 5:09 am ET1min read
On April 18, 2025, uniQure's stock surged by 38.55% in pre-market trading, marking a significant rise for the biotechnology company.
UniQure's stock price experienced a notable increase following the FDA's grant of Breakthrough Therapy designation to AMT-130, a treatment for Huntington's disease. This designation was based on clinical evidence from phase I/II trials, which demonstrated a meaningful slowing of disease progression. The designation is in addition to the Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug designation, and Fast Track designation, all previously granted by the FDA to AMT-130.
Huntington's disease is a rare, inherited neurodegenerative disorder for which there are currently no disease-modifying therapies available. The Breakthrough Therapy designation is expected to expedite the development and review of AMT-130, potentially bringing a new treatment option to patients suffering from this debilitating condition.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
RTX Stock Rallies 4.83% on $1.7B Patriot Contract Win, Geopolitical Tensions Drive Defense Demand
Dec.23 2025
Lam Research Drops 0.27% to Monthly Low Amid Catalyst Vacuum
Dec.23 2025
PowerBank (SUUN) Surges 36.17% on Strategic $41M Solar Deal PowerBank (SUUN) Surges 36.17% on Strategic $41M Solar Deal
Dec.23 2025
Carnival Corporation Shares Plunge 2.73% as Macroeconomic Headwinds Offset Record 2025 Earnings
Dec.23 2025
Nasdaq Composite Hits Monthly High with 0.84% Surge, Extends 6-Day Rally to 5.47% on Trump-Fed Rhetoric
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet